TGFB1 and cancer: Strategies aimed at modulating TGF-β signaling, such as TGF-β receptor inhibitors or Smad pathway inhibitors, hold promise for the treatment of cancer, fibrosis, and other diseases characterized by dysregulated angiogenesis.